Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2015 1
2016 2
2017 2
2019 3
2020 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Dexlansoprazole response"
Page 1
Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults.
Wu L, Liu J, Zheng Y, Zhai Y, Lin M, Wu G, Lv D, Shentu J. Wu L, et al. Clin Drug Investig. 2019 Oct;39(10):953-965. doi: 10.1007/s40261-019-00824-2. Clin Drug Investig. 2019. PMID: 31338800 Free PMC article. Clinical Trial.
A weak positive correlation between dexlansoprazole AUC(t) and baseline-adjusted TpH 4.0(%) over 0-24 h was observed, with Pearson correlation coefficients of 0.437 (p = 0.029), while no correlation was observed between AUC(t) and baseline-adjusted TpH 6.0(%) …
A weak positive correlation between dexlansoprazole AUC(t) and baseline-adjusted TpH 4.0(%) over 0-24 h was observed, with Pea …
First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.
Liang CM, Kuo MT, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC, Chuah SK; Taiwan Acid-Related Disease Study Group. Liang CM, et al. World J Gastroenterol. 2017 Dec 21;23(47):8395-8404. doi: 10.3748/wjg.v23.i47.8395. World J Gastroenterol. 2017. PMID: 29307999 Free PMC article. Clinical Trial.
An increasing trend toward a higher CSR was observed in the dexlansoprazole group at day 7 (55.3% vs 36.8%, P = 0.09). ...CONCLUSION: The overall CSR for GERD patients was similar at days 1-7 for both the dexlansoprazole and esomeprazole groups, although a hi …
An increasing trend toward a higher CSR was observed in the dexlansoprazole group at day 7 (55.3% vs 36.8%, P = 0.09). ...CONC …
Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
Chiang HH, Wu DC, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Yao CC, Tsai CE, Liang CM, Wang YK, Wang JW, Huang CF, Chuah SK; Taiwan Acid-Related Disease Study Group. Chiang HH, et al. Drug Des Devel Ther. 2019 Apr 26;13:1347-1356. doi: 10.2147/DDDT.S193559. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31118571 Free PMC article. Clinical Trial.
Results: The GERDQ scores at 4-, 8-, 12-, 16-, 20-, and 24-week posttreatment were less than the baseline score. ...Conclusions: This study suggests that the symptom relief effect for GERD after 24 weeks was similar for dexlansoprazole and esomeprazole. De …
Results: The GERDQ scores at 4-, 8-, 12-, 16-, 20-, and 24-week posttreatment were less than the baseline score. ...Conclusion …
Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Vakily M, et al. Curr Med Res Opin. 2009 Mar;25(3):627-38. doi: 10.1185/03007990802693883. Curr Med Res Opin. 2009. PMID: 19232037
The percent of time pH > 4 over 24 h values were 59.2% and 66.7% for dexlansoprazole MR 30 and 90 mg, respectively. No appreciable additional gain in the pharmacodynamic response was predicted for dexlansoprazole MR 120 mg. ...Exposure-response …
The percent of time pH > 4 over 24 h values were 59.2% and 66.7% for dexlansoprazole MR 30 and 90 mg, respectively. No appreciable …
Association Between Proton Pump Inhibitors and Microscopic Colitis.
Law EH, Badowski M, Hung YT, Weems K, Sanchez A, Lee TA. Law EH, et al. Ann Pharmacother. 2017 Mar;51(3):253-263. doi: 10.1177/1060028016673859. Epub 2016 Oct 13. Ann Pharmacother. 2017. PMID: 27733667 Review.
STUDY SELECTION: Full-text, English-language reports of case reports/series, observational studies, experimental studies, and systematic reviews/meta-analyses published between January 2000 to August 2016 were included. ...A review of the current body of evidence reveals a …
STUDY SELECTION: Full-text, English-language reports of case reports/series, observational studies, experimental studies, and systema …
Dexlansoprazole is Effective in Relieving Heartburn during the Fasting Month of Ramadan.
Rimmani HH, Rustom LBO, Rahal MA, Shayto RH, Chaar H, Sharara AI. Rimmani HH, et al. Dig Dis. 2019;37(3):188-193. doi: 10.1159/000496091. Epub 2019 Jan 9. Dig Dis. 2019. PMID: 30625462 Clinical Trial.
Mean heartburn severity score decreased from 2.5 1.0 to 1.7 0.8 (p = 0.001). Early response was higher in patients with GERDQ scores 8 (p = 0.012). CONCLUSION: Dexlansoprazole is effective in the treatment of heartburn during Ramadan. ...
Mean heartburn severity score decreased from 2.5 1.0 to 1.7 0.8 (p = 0.001). Early response was higher in patients with GERDQ …
Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
Lin XH, Luo JC, Ting PH, Chang TE, Huang YH, Hou MC, Lee FY. Lin XH, et al. J Gastroenterol Hepatol. 2020 Dec;35(12):2096-2102. doi: 10.1111/jgh.15093. Epub 2020 May 19. J Gastroenterol Hepatol. 2020. PMID: 32401385 Clinical Trial.
Multivariate logistic regression analysis showed that the use of dexlansoprazole, presence of dyslipidemia, and typical GERD symptoms (acid reflux and heartburn) were predictors for symptom response for cough; the use of dexlansoprazole and presence of …
Multivariate logistic regression analysis showed that the use of dexlansoprazole, presence of dyslipidemia, and typical GERD symptoms …
The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.
Dabholkar AH, Han C, Paris MM, Perez MC, Atkinson SN, Peura DA. Dabholkar AH, et al. Aliment Pharmacol Ther. 2011 Feb;33(3):366-77. doi: 10.1111/j.1365-2036.2010.04519.x. Epub 2010 Nov 30. Aliment Pharmacol Ther. 2011. PMID: 21118280 Free article. Clinical Trial.
BACKGROUND: Dexlansoprazole MR is a Dual Delayed Release formulation of dexlansoprazole, an enantiomer of lansoprazole, designed to extend the duration of acid suppression. ...No clinically meaningful change in any clinical laboratory parameters was noted. As expect …
BACKGROUND: Dexlansoprazole MR is a Dual Delayed Release formulation of dexlansoprazole, an enantiomer of lansoprazole, design …
Randomized controlled trial comparing esophageal dilation to no dilation among adults with esophageal eosinophilia and dysphagia.
Kavitt RT, Ates F, Slaughter JC, Higginbotham T, Shepherd BD, Sumner EL, Vaezi MF. Kavitt RT, et al. Dis Esophagus. 2016 Nov;29(8):983-991. doi: 10.1111/dote.12398. Epub 2015 Jul 30. Dis Esophagus. 2016. PMID: 26228516 Clinical Trial.
Subsequent to randomization and endoscopy, all patients received fluticasone and dexlansoprazole for 2 months. The primary study outcome was reduction in overall dysphagia score, assessed at 30 and 60 days post-intervention. ...No significant difference in dysphagia …
Subsequent to randomization and endoscopy, all patients received fluticasone and dexlansoprazole for 2 months. The primary study outc …
Investigation of the interaction between proton pump inhibitors and clopidogrel using VerifyNow P2Y12 assay.
Lin SF, Lin PC, Chang CC, Chang WL, Chu FY. Lin SF, et al. Medicine (Baltimore). 2020 Dec 11;99(50):e23695. doi: 10.1097/MD.0000000000023695. Medicine (Baltimore). 2020. PMID: 33327360 Free PMC article.
BACKGROUND: Randomized trials and observation studies have revealed conflicting results regarding the interaction between clopidogrel and proton pump inhibitors (PPIs). ...Patients treated with lansoprazole, esomeprazole, pantoprazole, and rabeprazole exhibited no signific …
BACKGROUND: Randomized trials and observation studies have revealed conflicting results regarding the interaction between clopidogrel …